(Breast Cancer) Efficacy of Verzenio + Fulvestrant?
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
On September 29, 2019, George W. Sledge Jr. published in the medical journal The Lancet the efficacy and safety results of CDK4/CDK6 cyclin-dependent kinase inhibitor Verzenio (abemaciclib) in patients with hormone receptor-positive, HER2-negative breast cancer after endocrine therapy from the MONARCH2 Phase III clinical trial.
The MONARCH2 trial was a multicenter, double-blind Phase III trial that randomized patients with hormone receptor-positive, HER2-negative breast cancer after endocrine therapy (N=669) in a 2:1 ratio. The primary endpoint was progression-free survival (PFS); the secondary endpoint was overall survival (OS).
- Verzenio + fulvestrant group (28-day cycle, Verzenio 150 mg twice daily + fulvestrant 500 mg; N=446)
- Placebo + fulvestrant group (28-day cycle, placebo + fulvestrant 500 mg; N=223)
Patient Characteristics:
Median age — Verzenio group: 59 years (32–91); Placebo group: 62 years (32–87)
Race — Verzenio group: Asian 33.4%, White 53.1%, Other 6.5%; Placebo: Asian 29.1%, White 61.0%, Other 5.8%
ECOG performance status — Verzenio group: ECOG 0: 59.2%, ECOG 1: 39.5%; Placebo: ECOG 0: 61.0%, ECOG 1: 39.0%
Prior therapy before endocrine treatment — Verzenio group: neoadjuvant/adjuvant chemotherapy 59.0%, treatment at metastasis 38.3%; Placebo: neoadjuvant/adjuvant chemotherapy 59.6%, treatment at metastasis 38.1%
Prior aromatase inhibitor therapy — Verzenio group: 70.9% with, 29.1% without; Placebo: 66.8% with, 33.2% without
Metastasis sites — Verzenio group: visceral 54.9%, bone 27.6%, other 16.8%; Placebo: visceral 57.4%, bone 25.6%, other 17.0%
Trial Results: The secondary endpoint median OS was: Verzenio group 46.7 months vs. placebo group 37.3 months. The Verzenio group's death risk was 24.3%, hazard ratio 0.757 — a significant improvement.
Subgroup analysis: Patients with visceral metastases showed a 32.5% reduction in death risk (HR 0.657), an improvement. Patients with bone-only metastases showed a 9.03% reduction in death risk (HR 0.907), an improvement.
Based on MONARCH2 results, George W. Sledge Jr. concluded: In hormone receptor-positive, HER2-negative breast cancer patients after endocrine therapy, CDK4/CDK6 cyclin-dependent kinase inhibitor Verzenio improved overall survival compared to placebo.
Source: The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy — MONARCH 2: A Randomized Clinical Trial. (JAMA Oncol. 2019 Sep 29. doi: 10.1001/jamaoncol.2019.4782.)
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5